We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-6.61%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$670M
AUM Growth
+$109M
(+19%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
21.49%
Top 10 Holdings %
Top 10 Hldgs %
59.4%
Holding
184
New
14
Increased
76
Reduced
55
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$71.8M |
| 2 |
WPZ
Williams Partners L.P.
WPZ
|
+$17.8M |
| 3 |
BPL
Buckeye Partners, L.P.
BPL
|
+$15M |
| 4 |
Enterprise Products Partners
EPD
|
+$13.8M |
| 5 |
Energy Transfer Partners
ET
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$45.5M |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$34.1M |
| 3 |
Marathon Petroleum
MPC
|
+$6.13M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.81M |
| 5 |
ProShares Ultra S&P500
SSO
|
+$4.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 73.91% |
| 2 | Healthcare | 7.71% |
| 3 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGYP
51
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.1M | 0.16% |
247,030
+185,922
| +304% | +$767K |
|
52
Nektar Therapeutics
NKTR
$2.34B
| $1.1M | 0.16% |
3,742
-1,925
| -34% | -$556K |
|
|
MNTA
53
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.09M | 0.16% |
64,489
-8,171
| -11% | -$124K |
|
54
Ligand Pharmaceuticals
LGND
$6.06B
| $1.09M | 0.16% |
14,342
-1,114
| -7% | -$77.9K |
|
55
Incyte
INCY
$23.3B
| $1.08M | 0.16% |
8,619
-1,490
| -15% | -$190K |
|
56
Neurocrine Biosciences
NBIX
$17.5B
| $1.08M | 0.16% |
23,551
+17,076
| +264% | +$828K |
|
57
Vertex Pharmaceuticals
VRTX
$120B
| $1.07M | 0.16% |
8,300
-4,918
| -37% | -$592K |
|
58
Regeneron Pharmaceuticals
REGN
$68.3B
| $1.07M | 0.16% |
2,171
-543
| -20% | -$238K |
|
59
Sarepta Therapeutics
SRPT
$1.68B
| $1.05M | 0.16% |
31,233
-3,303
| -10% | -$108K |
|
60
Ionis Pharmaceuticals
IONS
$9.23B
| $1.04M | 0.15% |
20,375
-1,506
| -7% | -$70.1K |
|
61
United Therapeutics
UTHR
$26.4B
| $1.03M | 0.15% |
7,952
+454
| +6% | +$56.6K |
|
|
ICPT
62
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.03M | 0.15% |
8,501
-1,424
| -14% | -$165K |
|
|
MDCO
63
DELISTED
Medicines Co
MDCO
| $1.03M | 0.15% |
27,060
-1,191
| -4% | -$53K |
|
64
BioMarin Pharmaceuticals
BMRN
$11.4B
| $1.02M | 0.15% |
11,260
-838
| -7% | -$76.2K |
|
|
PGNX
65
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.01M | 0.15% |
148,929
+33,629
| +29% | +$248K |
|
66
Halozyme
HALO
$9.59B
| $1M | 0.15% |
78,354
-15,945
| -17% | -$213K |
|
|
TSRO
67
DELISTED
TESARO, Inc.
TSRO
| $993K | 0.15% |
7,097
-906
| -11% | -$131K |
|
68
Omeros
OMER
$744M
| $938K | 0.14% |
47,112
-53,412
| -53% | -$932K |
|
|
SGEN
69
DELISTED
Seagen Inc. Common Stock
SGEN
| $838K | 0.13% |
16,188
-273
| -2% | -$17.4K |
|
|
SEP
70
DELISTED
Spectra Engy Parters Lp
SEP
| $781K | 0.12% |
18,201
+5,974
| +49% | +$260K |
|
71
Direxion Daily Energy Bull 2X ETF
ERX
$247M
| $578K | 0.09% |
2,306
+16
| +0.7% | +$4.47K |
|
|
FCH.PRA
72
DELISTED
Felcor Lodging Tr Ser A Cum Cv
FCH.PRA
| $519K | 0.08% |
18,616
+6,488
| +53% | +$169K |
|
73
Vanguard Real Estate ETF
VNQ
$39.1B
| $477K | 0.07% |
5,726
+1,311
| +30% | +$109K |
|
|
PTLA
74
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $456K | 0.07% |
8,122
-7,246
| -47% | -$290K |
|
|
IMGN
75
DELISTED
Immunogen Inc
IMGN
| $452K | 0.07% |
+63,629
| New | +$291K |
|
Similar funds
NCM
OC
SSA
LIWM
VFG
IAM
1M
GC
Virtus ETF Advisers's Q2 2017 Portfolio in Review
As of Q2 2017, Virtus ETF Advisers held 184 positions worth $670M, up 19% from $562M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Virtus ETF Advisers deployed $144M of net new capital in Q2 2017, opening 14 new positions and adding to 76 existing holdings. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
By sector, the portfolio is most concentrated in Energy at 74% of assets, up from 70% a quarter earlier, followed by Healthcare and Utilities.
On the sell side, the largest reduction was Marathon Petroleum, an estimated $6.13M trimmed.
- Virtus ETF Advisers's largest Q2 2017 buy was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
- Virtus ETF Advisers added most to Energy Transfer Partners, L.P. in Q2 2017, an estimated $71.8M increase.
- Virtus ETF Advisers's biggest Q2 2017 reduction was Marathon Petroleum, cutting an estimated $6.13M.
- Virtus ETF Advisers fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $45.5M.
- Virtus ETF Advisers's ten largest holdings make up 59% of its $670M portfolio in Q2 2017.
- Virtus ETF Advisers opened 14 new positions and closed 39 in Q2 2017.
- Virtus ETF Advisers's portfolio value rose 19% quarter-over-quarter to $670M.
Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.